Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Catrin Heim"'
Autor:
Catrin Heim, Laura M. Moser, Herman Kreyenberg, Halvard B. Bonig, Torsten Tonn, Winfried S. Wels, Elise Gradhand, Evelyn Ullrich, Michael T. Meister, Marian Groot Koerkamp, Frank C. P. Holstege, Jarno Drost, Jan-Henning Klusmann, Peter Bader, Michael Merker, Eva Rettinger
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionMetastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies. Applying chimeric antigen receptor (CAR
Externí odkaz:
https://doaj.org/article/a67ec3b12510448385698d63f9fbce7d
Autor:
Michael Merker, Juliane Wagner, Hermann Kreyenberg, Catrin Heim, Laura M. Moser, Winfried S. Wels, Halvard Bonig, Zoltán Ivics, Evelyn Ullrich, Thomas Klingebiel, Peter Bader, Eva Rettinger
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
High-risk rhabdomyosarcoma (RMS) occurring in childhood to young adulthood is associated with a poor prognosis; especially children above the age of 10 with advanced stage alveolar RMS still succumb to the disease within a median of 2 years. The adve
Externí odkaz:
https://doaj.org/article/c9e26cde1be642568cc2b4bdadeffe17
Autor:
Leonie D. H. Gossel, Catrin Heim, Lisa-Marie Pfeffermann, Laura M. Moser, Halvard B. Bönig, Thomas E. Klingebiel, Peter Bader, Winfried S. Wels, Michael Merker, Eva Rettinger
Publikováno v:
Cancers, Vol 13, Iss 6, p 1443 (2021)
The dismal prognosis of pediatric and young adult patients with high-risk rhabdomyosarcoma (RMS) underscores the need for novel treatment options for this patient group. In previous studies, the tumor-associated surface antigen ERBB2 (HER2/neu) was i
Externí odkaz:
https://doaj.org/article/2c7b8ab2be7c4ea6903979c671eee640
Autor:
Catrin Heim, Winfried S. Wels, Halvard Bonig, Peter Bader, Lisa-Marie Pfeffermann, Laura M Moser, Michael Merker, Leonie D H Gossel, Eva Rettinger, Thomas Klingebiel
Publikováno v:
Cancers, Vol 13, Iss 1443, p 1443 (2021)
Cancers
Volume 13
Issue 6
Cancers
Volume 13
Issue 6
Simple Summary In this study, we apply the ERBB2-chimeric antigen receptor (CAR)-modified natural killer (NK) cell line NK-92 (NK-92/5.28.z), a well-defined, good manufacturing practice (GMP)-compliant, third-party, off-the-shelf immune effector cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::706b503fc5b0b4b67ad4170ac34a1e73
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62465
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62465